# Zoetis Inc. (ZTS)

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-12  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/ZTS/primer

## Business Model

---
ticker: ZTS
step: 01
generated: 2026-05-12
source: quick-research
---

### Zoetis Inc. (ZTS) — Business Overview

#### Business Description
Zoetis is the world's largest pure-play animal health company, spun out of Pfizer in 2013. The company discovers, manufactures, and commercializes a comprehensive portfolio of medicines, vaccines, diagnostics, and digital health platforms for both companion animals (dogs, cats, horses) and livestock (cattle, swine, poultry, fish, sheep). The strategic narrative has shifted decisively toward companion animals — pets now generate ~65% of revenue — as pet-ownership rates and per-animal spending have outpaced livestock growth globally.

#### Revenue Model
Two species portfolios across two geographic segments (US + International):
- **Companion Animal (~65% of revenue):** Higher-margin, faster-growing, more recession-resilient. Anchored by dermatology (Apoquel, Cytopoint), pain (Librela, Solensia), and parasiticides (Simparica, Simparica Trio).
- **Livestock (~35% of revenue):** Cattle, swine, poultry, aquaculture, and sheep products. Slower growth, more commoditized, but provides global scale and emerging-markets exposure.

Revenue is generated through veterinarian-channel sales (~80% of companion animal goes through vet practices), plus direct-to-producer for livestock and limited e-pharmacy channels. Pricing has structural lift from biologic and monoclonal-antibody products commanding premium gross margins.

#### Products & Services
**Companion Animal:**
- **Dermatology:** Apoquel (oclacitinib — JAK inhibitor for canine pruritus), Cytopoint (lokivetmab — anti-IL-31 mAb), Itrafungol, Convenia
- **Pain (monoclonal antibodies):** Librela (bedinvetmab — anti-NGF mAb for canine OA pain), Solensia (frunevetmab — anti-NGF mAb for feline OA pain)
- **Parasiticides:** Simparica (sarolaner), Simparica Trio (sarolaner + moxidectin + pyrantel — flea/tick/heartworm), Revolution Plus, ProHeart
- **Vaccines:** Vanguard (canine), Felocell (feline), Versican
- **Diagnostics:** Vetscan (in-clinic blood analyzers), Vetscan Imagyst (AI-powered cytology)
- **Digital health:** Zoetis Reference Laboratories, Phovia, Vetscan OptiCell

**Livestock:**
- **Cattle:** BoviKalc, Bovi-Shield, Excede, Excenel, Synovex implants
- **Swine:** Suvaxyn, Lincomix, Improvest
- **Poultry:** Poulvac, Aviator, EuropharmaVet
- **Aquaculture:** Aquaflor, Aqualife, fish vaccines

**Pipeline:** Multiple next-generation monoclonal antibodies, long-acting parasiticides, and species-extension assets.

#### Customer Base & Go-to-Market
- **Companion animal customers:** Reached via ~80,000+ veterinary clinics globally; ~70%+ of companion-animal revenue is delivered through veterinarian-prescribed channels.
- **Livestock customers:** Direct sales to large cattle producers, hog and poultry integrators, dairy operations, and aquaculture operations. Long-cycle relationships with US and global agribusiness firms (Tyson, JBS, Smithfield, etc.).
- **Distribution:** 25 manufacturing sites globally + largest direct sales force in animal health. Smaller share via e-pharmacy / online vet channels.
- **Geographic mix:** ~55% US, ~45% International; emerging markets growing faster than developed.

No single customer represents material concentration; the fragmented vet-practice channel and global producer base diversify revenue risk.

#### Competitive Position
Zoetis is the global animal health leader with ~18% global market share — ahead of Boehringer Ingelheim Animal Health (~14%), Merck Animal Health (~13%), and Elanco (~10%). Key competitive advantages: (1) **Monoclonal antibody leadership** — first-mover in vet mAbs with Cytopoint (allergic skin), Librela (canine OA), and Solensia (feline OA); R&D head start measured in years, (2) **Dermatology franchise (Apoquel + Cytopoint)** — gold-standard for canine pruritus generating billions annually, though growth slowed in 2025 due to consumer-spending pressure and emerging competition, (3) **R&D scale** — >$650M annual R&D budget and deep pipeline in mAbs, parasiticides, and species-extension, (4) **Vertical integration** — 25 manufacturing sites and largest direct vet sales force sustain margins and customer reach, (5) **Diagnostics + digital platform** (Vetscan Imagyst AI cytology) creates an ecosystem moat with veterinary practices. Key challenges: emerging Apoquel competition (Galaxy / Modulis / cibinetide-class JAK inhibitors from Elanco, Boehringer), Librela neurological side-effect overhang (FDA "Dear Veterinarian" letter + label updates), consumer-spending pressure on pet care, and Elanco's accelerating innovation pipeline.

#### Key Facts
- Founded: 2013 (spun out of Pfizer Animal Health)
- Headquarters: Parsippany, NJ
- Employees: ~14,000
- Exchange: NYSE
- Sector / Industry: Health Care / Drug Manufacturers – Specialty & Generic
- Market Cap: ~$50B (May 2026)
- 12+ consecutive years of dividend increases since 2013 IPO

## Financial Snapshot

---
ticker: ZTS
step: 04
generated: 2026-05-12
source: quick-research
---

### Zoetis Inc. (ZTS) — Financial Snapshot

#### Income Statement Summary

| Metric | FY2022 | FY2023 | FY2024 | FY2025 | YoY (25v24) |
|--------|--------|--------|--------|--------|-------------|
| Revenue | $8.08B | $8.54B | $9.26B | $9.47B | +2.3% |
| Gross Margin | ~71% | ~71% | ~71% | ~71% | flat |
| Operating Margin (adj.) | ~37% | ~38% | ~39% | ~39% | flat |
| Net Income (GAAP) | $2.11B | $2.34B | $2.49B | $2.67B | +7.5% |
| EPS (diluted, GAAP) | $4.49 | $5.07 | $5.47 | $6.02 | +10.1% |

#### Cash Flow & Balance Sheet (FY2025)

| Metric | Value |
|--------|-------|
| Operating Cash Flow | ~$2.7B |
| Capex | ~$650M |
| Free Cash Flow | ~$2.0B |
| Cash & Investments | ~$2.0B |
| Total Debt | ~$6.5B |

#### Capital Return
- 12+ consecutive years of dividend increases since 2013 IPO
- Active share buyback program — typically $1–2B annually
- Capital priority: balanced between R&D reinvestment, dividend, buybacks

#### Key Ratios (approximate, May 2026)
- P/E (TTM, GAAP): ~19x | EV/EBITDA: ~14x | FCF Yield: ~4%
- Revenue Growth (TTM, organic operational): ~6% | Adj. Operating Margin: ~39%
- Stock price ~$116 — down ~30%+ from 52-week highs after Librela safety concerns + Q4 2025 weakness

#### Segment Mix (FY2024 — illustrative)
- Companion Animal: ~65% revenue, +14% operational growth
- Livestock: ~35% revenue, +5% operational growth
- US: ~55% revenue; International: ~45%

#### Top Franchises (illustrative)
- Simparica + Simparica Trio (parasiticides): $2B+ run-rate, growing 13–22%
- Apoquel + Cytopoint (dermatology): >$2B combined, but Q1 2026 -11% YoY under competition
- Librela + Solensia (pain mAbs): >$1B combined, growth tempered by safety concerns
- Vaccines: Vanguard, Felocell, Suvaxyn families
- Diagnostics: Vetscan platform expanding into AI cytology

#### Growth Profile
Zoetis is in a transition year. FY2025 organic operational growth slowed to mid-single-digits (vs. high-single / low-double historically) due to:
- Consumer-spending pullback on routine pet wellness (Gen Z/Millennial owners reducing vet visits in response to clinic price increases)
- Librela neurological safety signals leading to FDA "Dear Veterinarian" letter and label updates
- Emerging Apoquel competition from Elanco / Boehringer JAK alternatives
- Q1 2026 US revenue -8% to $1.09B

Underlying long-term thesis remains intact: only 1/3 of US dogs treated for parasites, only 12M of 32M itchy dogs use Zoetis dermatology products, and the renal mAb franchise targeting $3–4B TAM is in development for 2027 launch.

#### Forward Estimates
**2026 guidance:** Revenue $9.825–10.025B (+5% midpoint); GAAP diluted EPS $6.65–6.75; adjusted EPS $7.00–7.10. Below the company's historical 7–10% organic growth pattern, reflecting expected continued dermatology competition + cautious Librela ramp. Consensus 12-month price target ~$151 implies 30%+ upside. Bull-side scenarios pencil in successful Librela safety stabilization + 2027 renal mAb launch, returning growth to high-single / low-double-digits by 2027. Bear-side scenarios extend the consumer slowdown and dermatology share loss into 2027 with continued multiple compression.

## Recent Catalysts

---
ticker: ZTS
step: 12
generated: 2026-05-12
source: quick-research
---

### Zoetis Inc. (ZTS) — Investment Catalysts & Risks

#### Bull Case Drivers

1. **Long-term penetration runway in parasiticides + dermatology** — Only one-third of US dogs currently treated for fleas/ticks/heartworm; of ~32M itchy dogs, only 12M use Zoetis dermatology products — leaving 20M+ untreated. Simparica Trio holds 50% US clinic patient share for triple-combination prophylaxis (up from ~25% two years ago), with puppies already at two-thirds adoption signaling multi-year visibility.

2. **First-in-class monoclonal antibody platform extending into new species and indications** — Zoetis has a multi-year R&D lead in veterinary mAbs. Cytopoint (allergic skin), Librela (canine OA), and Solensia (feline OA) established the playbook; the renal mAb franchise targeting a $3–4B TAM enters regulatory submission in 2027 and could be the next billion-dollar franchise.

3. **Underlying pet-economy secular trend intact** — Pet ownership rates, premiumization (humanization of pets), and per-animal spending continue to grow globally. Diagnostics platform (Vetscan Imagyst AI cytology), digital health, and reference labs create ecosystem moats with veterinary practices that competitors cannot replicate quickly.

4. **Valuation reset creates entry opportunity** — Stock down ~30%+ from 52-week highs after Q4 2025 Librela / dermatology disappointment; trading at ~19x FY2025 EPS — toward the low end of the company's historical range. Mean sell-side PT of $151 implies 30%+ upside. The bear case appears largely priced in.

#### Bear Case Risks

1. **Librela neurological safety overhang** — FDA "Dear Veterinarian" letter and updated labels on Librela following reports of neurological side effects in some treated pets. Public perception risk, potential litigation, and slower-than-expected ramp could compromise the multi-billion-dollar OA pain franchise. Management has cut guidance partly on Librela softness.

2. **Apoquel + Cytopoint dermatology competition emerging** — Q1 2026 Apoquel + Cytopoint -11% YoY. Elanco, Boehringer, and others have launched or are advancing JAK inhibitor / anti-IL-31 alternatives. While Zoetis claims gold-standard efficacy, the first-mover monopoly is eroding faster than expected, and structural share loss would compress the company's most profitable franchise.

3. **Consumer-spending pullback on routine wellness** — Q1 2026 US revenue -8% YoY driven by softer companion-animal demand, price sensitivity at vet practices. Gen Z / Millennial pet owners pulling back on routine and wellness care in response to clinic price increases. This cyclical headwind exposes Zoetis's pricing power and could compress visit-frequency-driven products.

4. **Elanco accelerating innovation pipeline** — Elanco Animal Health (Zoetis's #4 competitor at ~10% share) has launched competitive canine parasiticides and a JAK inhibitor pipeline, plus integration synergies from the Bayer Animal Health deal. Several sell-side analysts now favor Elanco's growth trajectory over Zoetis through 2026.

#### Upcoming Events
- **Q2 2026 earnings**: Late July 2026 — focus on Librela safety updates, dermatology share trends, US visit trajectory
- **Librela clinical safety updates**: Periodic FDA / Zoetis communications through 2026
- **Q3 2026 earnings**: Late October 2026 — key for FY2027 commentary
- **2027 Renal mAb regulatory submission**: Major potential catalyst
- **Apoquel patent / formulation lifecycle decisions**: Throughout 2026/2027

#### Analyst Sentiment
Sell-side consensus is constructive but cautious: ~60% Buy / 35% Hold. Mean 12-month price target ~$151 (vs. current trading ~$116). Bulls expect Librela safety stabilization + 2027 renal mAb launch + dermatology defense to compound EPS growth back to high-single/low-double-digit; bears extend the consumer slowdown and dermatology share loss as multi-year drags. The principal divergence is whether the Q4 2025 stock crash was a buying opportunity or the start of a structural derating.

#### Research Date
Generated: 2026-05-12

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/zts
- Full research API: GET /api/v1/research/ZTS/memo
- Coverage universe: /stocks